HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (50) Citing Articles via Google Scholar Google Scholar Articles by Berruti, A. Articles by Angeli, A. Search for Related Content PubMed PubMed Citation Articles by Berruti, A. Articles by Angeli, A. Related Collections Proteomics and Protein Markers Endocrinology and Metabolism

Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases

^a Address correspondence to this author at: Clinica Medica, Oncologia Medica, Azienda Ospedaliera San Luigi di Orbassano, Regione Gonzole 10, 10043 Orbassano, Italy. Fax 39 11 9026676; e-mail dogliott{at}pasteur.sluigi.unito.it

Background: The alteration of the bone microenvironment as a consequence of skeletal metastases is poorly understood. The aim of this study was to search for patterns of bone markers in relation to primary tumor type, bone pain, and number of sites involved in patients with bone metastases.

Methods: We studied 323 patients with bone metastases from various primary malignancies. We sequentially measured the serum concentrations of bone alkaline phosphatase [by an electrophoretic technique (BALP)], carboxy-terminal telopeptide of type I collagen (ICTP), calcium (CaS), intact parathyroid hormone (PTH), and the fasting urinary excretion of calcium (Ca:Cr). Immunoradiometric serum bone alkaline phosphatase (I-BALP) and urinary excretion of deoxypyridinoline (DPYD) were also assessed in the 175 cases. Data were analyzed as a function of bone pain (assessed by a validated pain questionnaire), the number of radiographically confirmed sites of bone involvement, and the most frequent primary tumor types: breast cancer (BC; 124 patients), prostate cancer (PC; 90 patients), and non-small cell lung cancer (LC; 49 patients).

Results: Serum BALP and I-BALP correlated with the number of radiologically identified blastic bone lesions. BALP and I-BALP were more frequently increased in PC (72% for both measurements) than in BC (50% and 60%, respectively) or LC (3% and 5%, respectively; P <0.001 for BALP and P = 0.001 for I-BALP). ICTP and DPYD values did not differ among PC, BC, and LC, but they did show a direct relationship with the disease extent in bone (P <0.001). CaS and Ca:Cr did not vary significantly according to the bone tumor burden. Bone pain directly correlated with ICTP (P <0.001), DPYD (P = 0.002), CaS (P <0.002), and Ca:Cr (P = 0.001), whereas the relationship was inverse for serum PTH (P = 0.002). When patients were stratified according to the primary tumor, ICTP correlated with the bone pain in all subsets (P <0.005, <0.005, and <0.001 for BC, PC, and LC, respectively), as did CaS and Ca:Cr in LC patients (P = 0.01 and 0.02, respectively) but not in PC and BC patients.

Conclusions: The patterns of bone turnover markers differ among the primary tumor types. Both resorption and formation markers reflect the number of radiographically identified sites of bone metastases, whereas resorption markers and serum calcium but not formation markers correlate with bone pain.© 1999 American Association for Clinical Chemistry

The following articles in journals at HighWire Press have cited this article:

				G. G. Schwartz Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 478 - 483. [Abstract] [Full Text] [PDF]

				J-J Body, M Lichinitser, S Tjulandin, P Garnero, and B Bergstrom Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases Ann. Onc., July 1, 2007; 18(7): 1165 - 1171. [Abstract] [Full Text] [PDF]

				D. J. Leeming, M. Koizumi, I. Byrjalsen, B. Li, P. Qvist, and L. B. Tanko The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 32 - 38. [Abstract] [Full Text] [PDF]

				R. E. Coleman, P. Major, A. Lipton, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y. J. Hei, J. Seaman, et al. Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid J. Clin. Oncol., August 1, 2005; 23(22): 4925 - 4935. [Abstract] [Full Text] [PDF]

				J. E. Brown, R. J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, and R. E. Coleman Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors J Natl Cancer Inst, January 5, 2005; 97(1): 59 - 69. [Abstract] [Full Text] [PDF]

				B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]

				L. M. Demers Biochemical Markers in the Management of Patients with Metastatic Bone Disease Clin. Chem., August 1, 1999; 45(8): 1131 - 1132. [Full Text] [PDF]